Although further investigations are necessary to assess the effects of other SGLT2is aside from dapagliflozin, our observations of the results of SGLT2 knockdown suggest SGLT2 targeting as a novel strategy against ccRCC. This evidence concerns the gene SLC5A2 and nonpapillary renal cell carcinoma.